Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
P35251
UPID:
RFC1_HUMAN
Alternative names:
Activator 1 140 kDa subunit; Activator 1 large subunit; Activator 1 subunit 1; DNA-binding protein PO-GA; Replication factor C 140 kDa subunit; Replication factor C large subunit
Alternative UPACC:
P35251; A8K6E7; Q5XKF5; Q6PKU0; Q86V41; Q86V46
Background:
Replication factor C subunit 1, also known as Activator 1 140 kDa subunit, plays a crucial role in DNA replication and repair. It is essential for the elongation of primed DNA templates by DNA polymerase delta and epsilon, facilitated by its interaction with PCNA and activator 1. This protein binds to primer-template junctions and recognizes non-primer template DNA structures, indicating its significance in maintaining genomic stability.
Therapeutic significance:
The protein is linked to Cerebellar ataxia, neuropathy, and vestibular areflexia syndrome, a neurologic disease caused by intronic AAGGG repeat expansions affecting its gene. Understanding the role of Replication factor C subunit 1 could lead to novel therapeutic strategies for this and potentially other related genetic disorders.